ICOS and neoplasm: Many studies have focused on the ability of ICOS‐modulating agents to activate “cold tumors” and decrease Tregs, thus allowing T‐cell infiltration, which may create a tumor microenvironment more amenable to an anti‐tumor immune response [13].